AI in Pharma: Why Kate O’Reilly Says the Future of Healthcare Starts With Patients, Not Technology

Artificial intelligence (AI) is now making waves in the pharmaceutical and life sciences industry. Healthcare leaders are now dealing with the question: How can AI make patient outcomes better without losing sight of the people it’s designed to serve?

In the recent episode of Digital Pulse by Pharmatica, host Shubhangi Dua, Podcast Producer and B2B Journalist, sat down with Kate O’Reilly, President and Chair, Board of Directors, Healthcare Businesswomen’s Association Dublin Chapter and Healthcare Transformation Partner, Roche. They talk about the future of AI in pharmaceuticals and life sciences, patient engagement, and healthcare transformation.

O’Reilly draws from her experience as a pharmacist, her studies in neuroscience, digital health and healthcare system innovation. She tells Dua that healthcare needs a foundational mindset shift. Particularly, the industry is encouraged to move to patient-first rather than technology-forward. This means keeping technology as a secondary step to ensuring deeper, more structural patient inclusion. 

“Patients really need to have a permanent seat at the decision-making table,” O’Reilly stated, alluding to the fact that healthcare innovation should be anchored in the experiences of the people it ultimately serves.

The former pharmacist believes that technology solely will not determine if healthcare innovations are successful. The vision O’Reilly depicts is of patients becoming active participants across the end-to-end care journey, rather than passive recipients.

Why is Patient Inclusion Key to Successful Innovation in Pharma?

“Patient-centricity” is evidently one of the most used terms in healthcare and pharma over the past decade. However, according to O’Reilly, patient inclusion continues to evolve and remains one of the greatest enablers to the development of successful innovation. 

Healthcare requires a systemic change that puts patients at the centre of the decision-making process, O’Reilly discusses. By virtue of living with their conditions, they are experts in their own care and the only individuals involved in every single decision made along the end-to-end care journey. They hold critical insights about their care needs that may not be visible to clinicians or researchers. This is spotlighted as the “missing data,” O’Reilly explains, which can change the trajectory of outcomes using technology.

Also Read: Strategic Pharma Intelligence Drives Better Decisions in Life Sciences

How can AI drive more patient-centred healthcare? 

Instead of bringing lists of symptoms, patients can now bring clinicians' recommendations, summaries and individualised health insights, with the advent of AI platforms like ChatGPT. However, the real opportunity for AI lies in how patients communicate with their clinical teams, O’Reilly believes.

One example of this is its potential role in shared decision-making, an important component of “patient-centred care”, she explains.

In this context, there is a potential role for AI when it comes to better informing patients and supporting them in taking a more active role in their care journeys, and also for clinicians when it comes to preparing medical information in a format that is more “patient-oriented”. However, AI will not replace clinicians, O’Reilly asserts. AI is an augmentation tool: “It's not a substitute for medical expertise,” she explained.

Also Read: First Quarter 2026 State of Digital Health Funding

How AI is changing patient outcomes in pharma

Healthcare Transformation Partner at Roche illustrates favourable outcomes for patient-first technologies. 

One of the greatest values of digital innovation is its capacity for continuous data collection. Conditions like MS often involve symptom fluctuations over time. This means that isolated appointments often only capture a discrete snapshot of the patient's experience at a particular moment in time. Continuous data collection can help create a more accurate and nuanced understanding of patients' well-being.

As excitement for AI grows in healthcare, organisations risk getting distracted by the technology itself. Instead, O’Reilly calls for “needs-led” innovation, which involves rigorous, evidence-based assessment of the problem being solved for.

As she summarised, "We need to fall in love with the problem" in healthcare; creating great solutions means little if the initial problem was misunderstood.

Also Read: Where Healthcare AI Investment Is Going — And Where It Isn't

Key Takeaways

• True patient engagement ensures patients have a permanent seat at the decision-making table
• When it comes to advancing patient-centred healthcare, some of the greatest potential for AI lies in its capacity to transform how clinicians and patients communicate, and how patients engage in decisions about their care 
• Healthcare transformation should be underpinned by a “needs-led”, rather than solution-driven approach; otherwise we risk building brilliant solutions for problems that may not exist. 
• The user experience of the clinician cannot be ignored. Innovation only moves as fast as clinical adoption. Their readiness to embrace new tools is the bridge to patient impact.

Chapters

• 00:00 Introduction to Healthcare Transformation
• 03:49 The Role of Patient Engagement
• 08:50 AI's Impact on Patient-Provider Communication
• 12:49 Operationalising Patient Engagement
• 14:12 AI and Digital Health Innovations
• 18:31 Collaborative Initiatives in Healthcare
• 20:48 Future of Pharma and Patient Interaction
• 22:46 Integrating Real-World Insights
• 25:26 Patient-Centric Clinical Studies
• 27:28 Key Takeaways for Pharma Leaders